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PrP charge structure encodes 
interdomain interactions
Javier Martínez1, Rosa Sánchez1, Milagros Castellanos2, Natallia Makarava3, 
Adriano Aguzzi4, Ilia V. Baskakov3 & María Gasset1
Almost all proteins contain charged residues, and their chain distribution is tailored to fulfill essential 
ionic interactions for folding, binding and catalysis. Among proteins, the hinged two-domain chain 
of the cellular prion protein (PrPC) exhibits a peculiar charge structure with unclear consequences 
in its structural malleability. To decipher the charge design role, we generated charge-reverted 
mutants for each domain and analyzed their effect on conformational and metabolic features. 
We found that charges contain the information for interdomain interactions. Use of dynamic light 
scattering and thermal denaturation experiments delineates the compaction of the α-fold by an 
electrostatic compensation between the polybasic 23–30 region and the α3 electronegative surface. 
This interaction increases stability and disfavors fibrillation. Independently of this structural effect, 
the N-terminal electropositive clusters regulate the α-cleavage efficiency. In the fibrillar state, use 
of circular dichroism, atomic-force and fluorescence microscopies reveal that the N-terminal positive 
clusters and the α3 electronegative surface dictate the secondary structure, the assembly hierarchy 
and the growth length of the fibril state. These findings show that the PrP charge structure functions 
as a code set up to ensure function and reduce pathogenic routes.
The charge organization in proteins defines the inter- and intramolecular ionic interactions essential for 
folding, binding and catalysis1–3. Altered charges modify the structural dynamics, the aggregation, and 
amyloid formation propensity, among others, of elementary proteins processes in all protein conforma-
tional diseases4–14. In prion disorders, the prion protein (PrP), a two-domain chain with an N-terminal 
effector tail (FT) hinged to a C-terminal globular domain (GD), forms transmissible amyloids15,16. 
Although the information for both folding and misfolding is contained in the 90–231 sequence region, 
the regulatory role exerted by the charged FT and the pathogenicity of mutations related to exposed 
charges underline an intramolecular code that remains to be elucidated10,17–30.
PrP displays a peculiar charge pattern in its two-domain chain, with a polybasic FT and all acid resi-
dues located at the GD. The FT is composed of repeats flanked at either side by positively charged clus-
ters, known as CC1 (residues 23–30) and CC2 (residues 101–110). Despite its intrinsically disordered tail, 
the protein undergoes ligand-induced folding and can wrap around the GD facing the α 2–α 3 exposed 
surface, which induces compaction of the α -fold19,27,31,32. Removing the CC1 cluster alters the α -fold 
stability, early nucleation steps, the polymer shape and the prion propagation efficiency17,18,20–26,28–30. CC2 
plays a very active metabolic role, participating in both biogenesis and processing33,34. Importantly, its 
charge abrogation yields amyloids with PrPSc-like features35. The spacing between CC1 and CC2 affects 
disease onset, GD stability and the FT effector function28,30,36,37. On the contrary, the GD contains all the 
acid residues of the chain. Among them, D144, D147, D178, E196 and E211 (numbered according to the 
human sequence) are involved in salt bridges that either stabilize (α 1/α 3) or link structural elements (β 2 
to α 2 and α 1 to α 2/α 3)38–41. Other residues, such as E146 and E152 in α 1, D167 in β 2-α 2, and E200, 
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D202, E207, E221 and E228 in α 3, expose their side chains to solvent, thus defining electronegative sur-
face clusters39. Of these charges, the structural D144 and D147 residues and their respective salt bridges 
stabilize PrPC, preventing conversion to protease resistance forms, whereas D178, E196 and E211 are 
prone sites for pathogenic mutations upon charge alteration38,42. Moreover, pathogenic mutations, such 
as E200K and Q217R, and the dominant negative E219K polymorphism alter the α 3 surface electrostatic 
potential, inducing minor folding effects39.
To unveil the information encoded in the complementary solvent-exposed charge structure, we 
constructed several mutants consisting of charge reversions and inclusions and tested their effects on 
the properties of both the α -folded and fibrillar states. These modifications avoid the formation of 
non-polar surface patches resulting from abrogating charges and it solubility effect43. At the FT, both 
the CC1 and CC2 regions were modified by substituting their K residues with E (K2: K24EK27E, 
K4:K101EK104EK106EK110E and K6: K2–K4). At the GD, the α 3 electronegative surface was perturbed 
by replacing E200 and E221 with K and by replacing Q217 and Q219 with charged R and K, respectively. 
We found that charges dictate a variety of structural and metabolic traits mostly through communication 
between domains. Effects such as the stabilization of the native α -fold, dictating the efficiency of the 
α -cleavage, attenuating the fibrillation propensity and yielding the most benign amyloids suggest that 
the charge design ensures PrPC functions.
Results
To gain insight into the charge design of the PrP chain, we utilized reversion and insertion approaches 
using the rHaPrP (23–230) (PrP wt) as template (Fig. 1a). This choice preserved surface charge avoiding 
solubility effects resulting from charge abrogation43. At the FT, both the CC1 and CC2 charges were 
reversed (K2: K24EK27E, K4:K101EK104EK106EK110E and K6: K2-K4). At the GD, the α 3 charge 
surface was modified by independent E200K, Q217R, Q219K, and E221K substitutions. Of these chains, 
K4 is equivalent to MoFBOM122, E200K and Q217R are pathogenic mutations found in humans44,45, and 
Q219K represents the dominant-negative variant of MoPrP Q218K46. All of these chains were produced 
recombinantly, yielding cooperative folds with a predominantly α -helical secondary structure (Fig. 1b).
PrP charge structure encodes an interdomain interaction promoting the α-fold compaction. 
Because charges are fundamental for intra- and intermolecular interactions, we probed the fold hydro-
dynamic properties using dynamic light scattering (DLS) (Fig. 2). To minimize insolubility interferences, 
measurements were performed using 15 μ M protein concentrations at pH values of 4.5 and 6.5, for 
which open and closed PrP wt states have been reported, respectively27,40. Figure 2a shows that PrP wt 
yielded monodisperse species with RH of 3.2 ± 0.1 (pH 4.5) and 2.6 ± 0.1 (pH 6.5) nm, whereas its GD as 
PrPΔ 23–89 yielded an RH of 2.1 ± 0.1 nm at both pH values47,48. Of these values, only the 2.6 nm for the 
PrP wt and 2.1 nm for the PrPΔ 23–89 were comparable to the theoretical RH values of globular protein 
spheres with the same molecular weight (2.25 and 1.96 nm, respectively), whereas the value of 3.2 nm for 
the PrP wt at pH 4.5 deviated from the ideal behavior, agreeing with the open state indicated via NMR. 
Importantly, the RH values at pH 6.5 remained constant in the presence of 10 mM Tris used as a cation 
quencher, ruling out the effects of cation traces (Fig. 2a).
Figure 1. Charge structure of the PrP chain. (a) Modular organization of the PrP chain into an N-terminal 
domain (FT) hinged to a C-terminal globular domain (GD), displaying the location of the charged regions 
and their mutations that were considered in this study. Epitopes for Ab3531 and POM17 are depicted using 
the color codes of fluorescence microscopy. (b) Far-UV CD spectra in 10 mM MES pH 6.5 of PrP wt and of 
its charge and length mutants due to their α -folding.
www.nature.com/scientificreports/
3Scientific RepoRts | 5:13623 | DOi: 10.1038/srep13623
At pH 4.5 all charge mutants yielded an RH (approximately 3.2 ± 0.1 nm) similar to the PrP wt, rul-
ing out perturbations in the open state (Fig. 2b). On the contrary, at pH 6.5, the RH of K4 and Q219K 
decreased to 2.6 ± 0.1 nm, whereas the RH values of K2 (both independently or combined with K4 as 
K6), E200K, Q217R and E221K remained unaltered. The lack of an RH difference for these mutants 
suggests an impaired compaction and a structural role of CC1, E200, Q217 and E221 in such process. 
Given the hydrodynamic invariability of the GD and the pH-induced electropositive charge changes (His 
residues in octarepeats) in the FT, the impaired RH reduction for the CC1, E200, Q217 and E221 mutants 
suggests that compaction involves an electrostatic interaction between the electropositive CC1 and the 
electronegative α 3 surface, which is altered in Q217R. To further test this possibility, we constructed 
a K2-E200K mutant containing a double reversion and, after verifying its cooperative folding (Figs  1 
and 3a), we tested its hydrodynamic properties. Figure  2b shows that the K2-E200K mutant behaved 
similar to the PrP wt, supporting the idea that the α -fold undergoes a compaction due to a long-range 
electrostatic interdomain interaction between the CC1 and α 3 surface charges. The interaction driving 
the interdomain lock in monomeric PrP wt is weak, and NaCl concentrations above 50 mM provoke the 
emergence of species corresponding to the open (3.2 ± 0.1) and oligomeric (5.6 ± 0.2 nm) states (Fig. 2a), 
agreeing with the relevance of stabilizing factors such as coordinated cations27,49.
Charge structure regulates α-fold stability through interdomain interactions in the native 
and denature states. To gain insights on the effect of the PrP charge structure on its thermody-
namic stability, we analyzed the thermal denaturation curves, as shown in Fig. 3. It must be noted that 
measurements were performed in the absence of described interdomain cation stabilizers to avoid effects 
other than their complexation with His residues of the N-terminal octarepeats27,49. With the exception of 
K4, all of the thermal denaturations were reversible, as indicated by the recovery of at least 90% of the 
initial signal after cooling from the highest temperature. K4 denaturation was irreversible, and insolu-
ble aggregates were detected upon cooling from the highest temperature (data not shown). Figure 3a,b 
show that the mutants with impaired compaction, such as K2, K6, E200K, Q217R, E221K and Δ 23–89, 
unfolded with Tm values lower than that of wt PrP. This effect varied according to K6 ≈ E221K ≈ Q217R 
> Δ 23–89> E200K ≈ K2, leading to decreases in the free energy of unfolding of about 1.2–6 kJ/mol. 
On the contrary, Q219K and K2-E200K, which undergo compaction, exhibited a PrP wt-like denatura-
tion profile. Notably, the K4 mutant, exhibiting PrP wt-like hydrodynamic properties, yielded the most 
thermally labile fold, possibly due to its singular irreversible denaturation. Thus, with the exception of 
Figure 2. Effect of charges on the PrP hydrodynamic features. (a) Mass size distributions of PrP wt and 
PrPΔ 23–89 as a function of pH and NaCl concentration. The theoretical values of RH for spheres with 
similar MWs to PrP wt and PrPΔ 23–89 are 2.25 and 1.96 nm, respectively. (b) Mass size distributions 
of PrP mutants in 10 mM NaAc pH 4.5 (black) and 10 mM Mes pH 6.5 (green). The measurements were 
performed at 25 °C using at least two different protein batches. Column widths show the standard deviation 
among measurements. Arrows at the top indicate the different RH values.
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K4, these results indicate that altering the charges that mediate the interdomain lock decrease the native 
fold stability.
The destabilization pattern of the mutants precluding compaction agree with the effects described 
for the chains containing N-terminal truncations at pH > 6.0 and slightly differ from that described for 
PrP chains consisting in mutant GD moieties20,21,37,50–52 (Fig. 3b). By virtue of its additivity, the Δ G of 
folding of a two-domain protein (TD or full length) can be expressed as the sum of the contributions 
arising from the folding of each of domain (Δ GFT and Δ GGD) and from their interaction (Δ GFTGD). 
Since the Δ GFT and Δ GFTGD are linked in PrP, their sum (Δ G*FT) can be calculated as Δ G*FT = Δ G 
TD - Δ GGD. For the PrP wt and a GD consisting in PrPΔ 23–89, Δ G*FT corresponded to 3 ± 0.7 kJ/mol 
(− Δ Δ G* in Fig. 3b), which agree with the 3.2 ± 1 kJ/mol value that can be calculated for GD consist-
ing in PrPΔ 32–89 chains20. For mutants exhibiting either identical GD as K2 or negligible effects on 
its free energy of unfolding as E200K50,51, which increasing GD breathing facilitates M213 sulfoxida-
tion53, Δ G*FT can be approximated to Δ GTDwt-Δ GTDmutant difference (− Δ Δ G* in Fig. 3b). This approach 
yielded values of 1.2 ± 0.2 and 1.5 ± 0.7 kJ/mol for K2 and E200K respectively. Taken together the values 
of PrPΔ 32–89, K2 and E200K yielded an averaged estimation of Δ G*FT of approximately 2 kJ/mol. On 
the hand, for Q217R the Δ Δ G*Q217R reported for the GD chains was − 8.9 ± 2 kJ/mol50,51 and the cal-
culated for the TD amounted to − 5.8 ± 1 kJ/moly. As with Q217R, K6 reversing the charge of FT flanks 
provoked a similar Δ Δ G* of − 6.2 ± 1 kJ/mol. The higher destabilization of Q217R and K6 compare to 
PrP Δ 23–89 suggested that in these mutants their charge changes affected interdomain interactions not 
only in the native state but also in their denature state54.
Charges are gatekeepers of PrP fibrillation. Although most PrP amyloids generated in vitro lack 
the infectivity and proteolytic signatures of PrPSc, their formation models the chain propensity and the 
conformational changes required for GD self-assembly55,56. To test whether the charge structure, through 
either the α -fold stabilization described above or the initial self-assembly step, impacts the fibrillation, 
we performed time-dependent Thioflavin T (ThT) binding experiments using the various PrP chains 
at pH 6.5 and calculated the lag-phase as indicator of propensity (Fig. 4). To induce the required mild 
denaturation, we used either 2 M GdnCl (conventional ionic media) or 3 M urea containing 50 mM 
NaCl (low salt). As anticipated from the exposed character of the mutated charges and the high ionic 
strength of the media, fibrillation in 2 M GdnCl (Fig.  4a) yielded lag-phases that were roughly similar 
for all chains, with minor reductions (K2,K4) or enhancements (K6) (Fig. 4c). On the contrary, reactions 
Figure 3. Effect of domain charges on the PrP stability. (a) Thermal denaturation of PrP wt and mutants. 
The unfolded fraction was calculated using the Ѳ222 temperature function according to a two-state transition, 
as described48. (b) Differences in the unfolding temperature (Δ Tm) and in the free energy of unfolding 
(Δ Δ G*) induced by the charge mutations. Δ Tm is the difference between the denaturation temperature of 
PrP mutant (PrPmut or PrP90−231 wild type) and full length PrPwt (Tmmut − Tmwt). Tm values were obtained 
as the midpoints of the temperature denaturation curves. Δ Δ G* was obtained as Δ H,wt × (1− Tmwt/
Tmmut), where Δ HvH is the van´t Hoff enthalpy of PrP wt denaturation (255 kJ/mol). Δ Δ G* < 0 indicates a 
destabilization of the mutant chain compared to the wt. Displayed data are the average of three independent 
measurements, performed with at least two different protein batches. Error bar represents the standard 
deviation (s.d.). Calculations for K4 were omitted given its irreversible denaturation.
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in the low salt media containing 3 M urea and 50 mM NaCl revealed that with the exception of Q219K, 
all mutants form fibrils faster than the PrP wt as indicated by their higher lag-phases (Fig. 4b,c). Kinetic 
curves also showed that charge changes in the GD (E200K, Q217R, Q219K and E221K) decrease the 
ThT fluorescence increment linked to fibrillation predominantly under low salt (Fig.  4a,b), suggesting 
off-pathway events.
The observed reduction in the lag-phase in the low salt reaction media in K2, K4, K6, E200K, Q217R 
and E221K variants indicated that CC1, CC2 and the α 3 electronegative caps function as fibrillation 
gatekeepers. Since K2, K6, E200K, Q217R and E221K impeded domain compaction and K4, with pre-
served compaction, lack the charges preventing the PrP fibril N-terminal packing35, together their effects 
suggest that charges regulate fibrillation propensity through their role in both the native fold compaction 
and the packing of critical regions for the seed stability. This charge effect agree with the increased pro-
pensity of PrP Δ 23–89 compared to the full length chain57,58 and the dependence of anionic cofactors 
for functional fibrillation59.
FT charges regulate the efficiency of C1 production. PrP processing into C1 chains is essen-
tial for the abrogation of prion formation and propagation, involving a complex cleavage within the 
interdomain hinge (around residue 110)60–62. To test whether the PrP charge structure plays a role in 
this processing, CHO cells were transfected with plasmids coding for PrP wt or its mutants, and the 
expressed chains were analyzed using POM 17 after PNGaseF digestion. Figure 4d,e shows that among 
the different PrP chains, only K2, K4 and their combination as K6 drastically reduced the efficiency of C1 
production compared to wt PrP, which is in agreement with previous reports that showed impaired C1 
production for mouse variants of K4 and PrPΔ 23–31 in both Hpl cells and transgenic mice22,25. On the 
contrary, the mutants including modifications of the α 3 surface charge impairing the interdomain lock, 
such as E200K, Q217R and E221K, yielded C1 levels similar to the PrP wt (Fig. 4d,e). Differences in the 
dependence of C1 production on the charge structure of either domain indicated that processing through 
the α -cleavage site is highly dependent on the FT charge structure but fairly independent of their role in 
Figure 4. Charge changes modify the fibrillation propensity and processing of PrP. Time-dependence 
of ThT binding of the PrP wt and mutants (40 μ M protein concentrations) in 50 mM MES pH 6.5 at 37 °C 
containing (a) 2 M GdnCl and (b) 3 M urea and 50 mM NaCl. The curves represent the average of three 
independent measurements, performed in triplicate. (c) Lag-phases of the fibrillation reactions of the PrP 
wt and mutants in 50 mM Mes pH 6.5 containing either 2 M GdnCl or 3 M urea with 50 mM NaCl. The 
depicted values correspond to three independent experiments, each performed in triplicate. (d) Western blot 
of PNGase-treated cell lysates of CHO cells transfected with PrP wt and the charged mutants. Detection was 
performed using POM17, and the positions of the full-length (FL) and N-terminal-truncated (C1 fragment) 
chains are depicted. (e) Variations in the C1/FL ratio of the PrP chains. Quantifications are the average of 
two independent transfection assays. Error bar represents the standard deviation (s.d.). *p < 0.01.
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driving the α -fold compaction. Thus, C1 production may require the recognition of the FT through its 
charge clusters by an unknown anionic ligand52,63–65, implying conditions with unlocked α -fold. These 
results suggest that the PrP charge structure regulates processing through its role in interactions.
Charges impact the secondary to quaternary structure of the fibrils. Similar to the α -folded 
wt PrP chain, variants with altered charge structure form fibrils that differ in their shape and 
proteinase-resistant core21,35. To gain insight into the effects of the charged design on the fibril structure 
and its properties, we used the reaction conditions yielding PrP wt S-fibrils with resolution for imaging 
analysis. S-fibrils, produced under slow orbital agitation as opposed to the fast rotation leading to the 
R-polymorph, are featured by a β -sheet-like far-UV CD spectrum along with a thin and curvy fibril 
topology that expose the 90–102 region while partially shield the POM17 epitope66 (Figs 5–7). It must be 
stressed that this fibrillation reaction was performed in the presence of 2 M GndCl, which abrogates the 
charge effects on the native α -fold and permits the assignation of the deviations from the wt behavior to 
differences in the assembly process. Fibrils formed by all PrP mutants displayed a reduced specific ThT 
binding, suggesting major structural differences (Fig. 5a).
Among the fibrils, only those formed by Q219K exhibited an S-like CD spectrum (Fig. 5b), whereas 
the assemblies formed by K2, K4, K6, E200K, Q217R and E221K displayed R-like CD spectra featuring 
a higher negative ellipticity, a minimum at 207 nm, and a shoulder at 217 nm of the β -sheet and turn 
structures (Fig. 5b). These data suggest a strict dependence of the S-fibril on CC1, CC2, and α 3 surface 
charges. Because only the R-type fibril exhibited in vivo infectivity, the PrP charge structure appears to 
drive the fibrillation path to the less pathogenic S-type state67. The blockage of S-fibril type formation 
in K2, K4, K6, E200K, Q217R and E221K mutants also suggest that these charges may behave as sites 
for cofactor binding that, through their shielding, may shift the conversion route to the most infectious 
path35,68,69. Accordingly, in addition to known anionic cofactors which may function recognizing CC1 
and CC2 regions may be molecules that exhibiting a basic charge would produce similar effects shield-
ing the α 3 surface charges , which would amplify the group of molecules functioning as cofactor in 
conversion35,59,68,69.
The Q219K substitution forms S-type-fibrils as PrP wt, but their assembly exhibited several differ-
ences. First, AFM imaging revealed that the Q219K fibrils, which were similar in dimension to those 
formed by the PrP wt, displayed a high degree of lateral association, yielding fibril layers rarely observed 
in PrP wt (Fig.  6). Second, the immunofluorescence analysis resolving fibrils in the μ m range showed 
that in the wt and the mutant fibrils, the 90–102 (red, Ab3531 epitope) region is exposed along the fibril 
Figure 5. Properties of the PrP wt and mutant fibrils. (a) Specific ThT binding of the PrP wt and mutant 
fibrils. Typically 50 μM of fibrils in 10 mM ammonium acetate pH 5 were incubated for 10 min with ThT 
(15 μ M) before fluorescence determination. ThT fluorescence intensities were corrected for the background 
(absence of fibrils) and divided by the protein amount in the pellet of a 12000 rpm 20 min centrifugation. 
The depicted data represent the average of two independent experiments performed in duplicate (*p < 0.01). 
(b) Far-UV CD spectra of the PrP wt and mutant assemblies in 10 mM ammonium acetate pH 5. The fibrils 
were formed in 50 mM MES pH 6.5 containing 2 M GdnCl at 37 °C under continuous rotation at 24 rpm, 
and then dialyzed against 10 mM ammonium acetate pH 5.
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axis, whereas POM17 epitopes (140/145 region) were detected as discrete regularly spaced dots (green), 
which after treatment with 3 M GdnCl become disrupted in the wt fibrils but persist in the Q219K fibrils 
(Fig. 7a). These differences in the POM17/Ab3531 overlap both in the absence and presence of denatur-
ant treatment are depicted in Fig. 7b.Thus, the lateral association and the attenuated surface reactivity of 
the Q219K fibrils may presumably contribute to the dominant-negative property of this charge insertion.
The K2 fibrils were thinner than the wt fibrils and tending to arrange into Y-shapes (Fig.  6). The 
immunofluorescence analysis revealed that the POM17 epitope was fully exposed in the absence of dena-
turant treatment (Fig. 7). On the contrary, K4 and K6 formed thick fibrils, indicating a higher assembly 
complexity. Of them, the peculiar stacking of the K6 assemblies resembled the aggregates of PrP27–30 
rods35,70. Immunostaining revealed that the POM17 epitope was highly secluded in the K4 and K6 assem-
blies, resisting treatments, with distinct GdnCl concentrations (Fig. 7). These results indicate that CC1 
and CC2 charges, in addition to allowing for S-type fibrillation, govern the evolution of the hierarchical 
assembly and the surface exposure of the region 140–145. CC1 appeared to work during the initial 
assembly step involving the shielding of the 140–145 region, whereas CC2 in a dominant fashion func-
tioned during later assembly steps, compromising the discrete POM17 epitope exposure. These effects 
suggest that the FT charges modulate properties of the fibril state of the C-terminal domain.
Changes in the α 3 charge structure resulted in R-type (Fig. 5b). AFM imaging revealed thicker fibrils 
compared to those of the PrP wt and images that were rich in short structures, rod-shaped in E200K and 
Figure 6. Topology images of the PrP wt and mutant fibrils. (a) AFM images of the PrP wt and mutant 
fibrils corresponding to the topology mode. The z-axis was fixed for all graphs, and the color scale is 
displayed as an insert in the PrP wt panel. (b) Histogram of the width distribution of the distinct PrP 
assemblies.
www.nature.com/scientificreports/
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Q217R and spherical in E221K (Fig. 6). Interestingly, the E221K mutant revealed extremely thin, curvy 
fibrils emerging from the spherical aggregates (Fig. 6). The E200K and Q217R fibrils displayed a surface 
reactivity similar to that of the PrP wt but with green dots at reduced spacing, suggesting POM17 epitope 
location at the joint of the short rod-shaped structures (Fig.  7). In both assemblies, mild denaturing 
treatment increased POM17 staining but to a lesser extent that in the wt fibrils, suggesting differences 
in the folding of the 140–145 region. On the contrary, the E221K fibrils resembled those formed by K4, 
with a complete seclusion of the POM17 epitope and a discrete exposure upon treatment with 3 M GdnCl 
(Fig.  7). Taken together, these features suggest that the charges of the α 3 primarily regulate the fibril 
length by either limiting growth or promoting fragmentation and the exposure of the POM17 epitope.
Discussion
Here, we show that the PrP charge structure considered as solvent exposed contains information regard-
ing interdomain interactions in both the PrPC-like conformation and the fibrillar state. In the PrPC-like 
formation, FT wraps the GD via the interaction between the N-terminal polybasic motive (CC1) and the 
α 3 electronegative surface. This complementary charge interaction is relatively weak, and in the absence 
of stabilizers such bound Zn2+ the modifications provoked by the ionic strength or diminished surface 
electronegativity (single charge reversion or inclusions along the helix) impaired it. Notwithstanding, the 
interdomain interaction adds to the global fold a stabilization lower threshold of approximately 2 kJ/mol 
which interferes with fibrillation. Independent of this structural effect, the FT charge design also dictates 
the efficiency of cleavage between domains through the α -site indicating that the production of neuro-
protecting fragments involves conditions with unlocked domains. In the fibrillar state, the PrP charge 
structure regulates the assembly process, dictating the secondary structure of the scaffold, the allowance 
of different (initial, intermediate and late) assembly steps, and the polymer length.
The sequence of proteins contains the protein’s functional information, including signaling mecha-
nisms for maturation, sorting, covalent modification, and folding regulation, whereas other functions 
Figure 7. Surface reactivity of PrP wt and mutant fibrils. (a) Representative fluorescence images of the 
fibrils formed by the PrP wt and mutant fibrils stained with AB3531 (red) and POM17 (green). Pretreatment 
with 3 M GdnCl is indicated as 3 M. The white bar represents 5 μ m. (b) Effect of charges on the variation 
of the POM17 overlap with AB3531 (Manders overlap coefficient) based on the denaturant concentration. 
Error bar represents the standard deviation (s.d.).
www.nature.com/scientificreports/
9Scientific RepoRts | 5:13623 | DOi: 10.1038/srep13623
are encrypted and operate metabolically. The PrP sequence exhibits an unusual abundance of encrypted 
codes. The abundance of Met residues in the PrP chain allows for the translation of a minor chain 
that segregates out of the major secretory route, a structural regulation through a redox process, and 
a metabolically controlled substitution by SeMet71–73. Similarly, the His distribution entails a complex 
pH-regulated, cation binding trait in the FT that provides a diverse structural landscape with func-
tional consequences27,32,63,74. Regarding charges, the complementary polybasic stretches in the FT and 
electronegative surfaces from the GD folding provide the basis for molecular compaction and its reg-
ulation by FT and GD ligands. Charge structures also participate in the fibrillation process, bestowing 
interdomain-dependent and domain-specific growth and assembly features.
The PrP charge structure seems to encode information for latent states with balanced ligand binding 
functions. The interdomain lock, functionally in non-transmembrane PrP formations, may sense changes 
in the length and flexibility of the FT, which depend on the number of repeats, the pH and cation bind-
ing27,28,30,36,37,75. Indeed, the interaction can be isolated either under partial protonation of the octarepeat 
His, as described here, or stabilized by Zn2+ binding27 to ensure ionic strength resistance. FT ligands that 
recognize its charge clusters regulate the cleavage of domains, suggesting that this process that monitors 
the dose of prion precursors uses as substrate the unlocked domain molecule. On the other hand, GD 
ligands precluding the lock by shielding the interacting motives (POM 4,10,19 and α -219–232) or by 
providing steric impediments (POM1) allow for FT toxic signaling28,76, suggesting that at the cell surface 
PrPC may exit under the compact state. As in the GD the α 3 surface constitutes the prion binding site, 
its shielding by the interdomain lock may also interfere with prion amplification by competing with seed 
binding76. Moreover, the interdomain lock prevents fibrillation of PrP by stabilizing the α -fold, which 
could be utilized in therapeutic intervention using the lock state as a target.
The charge structure code also operates in the fibrillation path, dictating properties that compromise 
propagation and toxicity. Despite the differences with PrPSc, only R-type PrP fibrils exhibit in vivo prop-
agation, which are only found in mutants with a modified charge structure66. The PrP charges appear 
to drive the chain into the fibril structures with attenuated pathogenicity and provide sites for cofac-
tor action. Therefore, cofactors that bind to CC1 may regulate the initial steps, whereas cofactors that 
shield CC2, singly or combined with CC1, may drive the progression to the advanced assembly steps. 
These mechanistic hints agree with the mode of action of polyanions in previous conversion studies35,59. 
Moreover, the limits of assembly evolution due to FT charges are inversely correlated with the POM17 
epitope exposure. Because this region contains the DWED sequence, forming part of the α 1 in the α -fold 
and stabilized by salt bridges, it is tempting to postulate that the assembly involves its interaction with 
CC1. On the other hand, charged residues at either end of the α 3, which are part of the β -core but not 
engaged in β -sheets, mainly govern the fibril length. Changing these charges reduces the length, either 
impeding growth or favoring fragmentation, which increases the seed concentration and consequently 
the propagation efficiency77. Thus, α 3 mutations may strengthen their pathogenicity by optimizing their 
propagation through the seed concentration.
In conclusion, PrP charge design encodes several of structural and metabolic traits set up for ensuring 
function and diminishing pathogenic routes. These traits are: 1) shaping an interdomain lock, which 
prevents the FT from its toxic signaling and the GD from its prion receptor activity, 2) promoting the 
α -cleavage yielding anti-prion C1 chains and reducing the dose of chains with pro-prion activity, and 3) 
stabilizing the α -fold against conversion and if so allowing the less pathogenic assembly.
Methods
Production of PrP chains. rHaPrP (23–231) chains were produced from their pET11a constructs 
as described48,78, with minor modifications. Briefly, inclusion bodies were solubilized in 20 mM Tris pH 
7.5 containing 6 M GdnCl, 05 M NaCl and 2.6 mM imidazole, and after column loading 6 M GdnCl was 
replaced by 8 M urea. rHaPrP(90–231) was produced from a pET15b construct using thrombin diges-
tion to cleave the His-tag. The various mutants were produced via site-directed mutagenesis using the 
primers listed in Table S1. Before use proteins were equilibrated in the desired buffer (10 mM NaAc pH 
4.5 or 10 mM Mes at pH 6.5, unless stated) by extensive dialysis and cleared by centrifugation before 
concentration determinations48.
Dynamic Light Scattering. Dynamic light scattering (DLS) measurements were performed using 
a DynaPro spectroscatter (Wyatt Technology) with a 1.5-mm path length and a 12 μ l quartz cuvette. 
The average of 20–25 acquisitions of buffers and protein solutions (15 μ M protein concentrations) were 
filtered using a 0.1 μ m Whatman Anodisc-3 filters. The hydrodynamic radii (RH) and mass proportions 
(%) of the species were derived from the autocorrelation data assuming a model of n-monodisperse glob-
ular proteins and using the software provided by the manufacturer13,48. Measurements were performed 
in triplicate using two different protein batches. The theoretical hydrodynamic radius (RHT) for PrP wt 
chain was calculated using 0.73 cm3 g−1 and 0.35 g H2O (g protein)−1 for the particle specific volume 
and the hydration, as described47.
CD Spectroscopy. CD spectra were recorded in a Jasco-810 CD spectrometer with 15 μ M protein 
solutions in either 10 mM Mes at pH 6.5 or 10 mM ammonium acetate pH 5.0 using a 0.1-cm cuvette48. 
Thermal denaturation experiments were performed following the ellipticity changes at 222 nm upon 
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heating from 15 °C to 90 °C at a 1 degree/min heating rate and analyzed as a two-state transition as 
described48. Briefly, the changes in Ѳ222 with temperatures were normalized to the fraction of unfolded 
protein (fU) using fU(T) = (Ѳ222(T) − Ѳ222N(T))/( Ѳ222U(T)− Ѳ222N(T)), where N and U refer to the native 
and unfolded states, respectively. The value of fU was plotted as a function of temperature for the cal-
culation of Tm and Δ Hm. The experimental Tm values of mutants were converted into the apparent 
relative changes in free energy with respect to the wt protein (Δ Δ Gomut/wt) using the equation Δ Δ Gmut/
wt = Δ Hwt x (1 – Tmwt / Tmmut), where Tmwt and Tmmut are the Tm values for the wt and mutant protein, 
respectively, and Δ Hwt is the denaturation van´t Hoff enthalpy of the wt protein.
Fibril formation. The proteins in 5 mM MES pH 6.5 were cleared by centrifuging at 13200 rpm for 
20 min at 4 °C and placed at 40 μ M protein concentrations in 50 mM MES at pH 6.5 containing either 
2 M GdnCl and 3 M urea with 50 mM NaCl. For kinetic analyses, 0.2-ml samples containing 15 μ M ThT 
were placed in wells with a 3 mm glass ball. ThT binding was monitored at 37 °C, as described13,73. All 
measurements were performed in triplicate, and the experiments were repeated at least with two different 
protein batches. For imaging, fibrils were formed in 50 mM MES pH 6.0 containing 2 M GdnCl at 37 °C 
with continuous rotation at 24 rpm. After 100 h, the products were dialyzed against 10 mM ammonium 
acetate at pH 5.
Atomic force microscopy. First, 2-μ M fibril solutions were deposited onto freshly cleaved mica sur-
faces. After 10 min of adsorption, the samples were washed with H2O and dried with a stream of N2. 
AFM studies were performed using a MultiMode Veeco microscope with a 125-μ m lateral range and a 
5-μ m vertical range equipped with a J-scanner and a NanoScope IIIa controller, using rectangular can-
tilevers with tetrahedral tips for the dynamic mode in air (Olympus, OMCL-AC240TS)13. The analysis 
was performed using WSxM (Nanotec).
Fluorescence Microscopy. PrP fibrils were deposited onto Permanox 8-well Lab-Teks chamber 
slides and immunostained with rabbit anti-PrP Ab 3531 (1:1000, recognizes 90–102) and mouse POM17 
anti-PrP Ab (1:1000, recognizes 140–145), followed by goat anti-rabbit and goat anti-mouse antibodies 
labeled with Alexa-488 and Alexa-546, respectively (Invitrogen/Molecular Probes, 1:1000). Fluorescence 
images were captured using an Axioplan Universal Microscope (Zeiss) equipped with a DFC 350 FX 
digital camera (Leica) and a 100x objective. Processing and analyses were performed using WCIF ImageJ 
software79. Manders overlap coefficients were determined as the amount of Ab3531 signal overlapped 
with the POM17 stain with at least 20 independent fibrils.
Cell culture, transfections and processing analysis. Mutants were generated using pcD-
NA4.1-HaPrP(1–254) as a template (Table 1S)80. Transient transfections were performed using Chinese 
hamster ovary (CHO) cells and Fugene 6 as a transfection reagent (Roche), as described80. After 40 h, 
the cells were harvested via in situ lysis in a cold RIPA buffer (10 mM Tris-HCl pH 7.5, 100 mM NaCl 
10 mM EDTA, 0.5% Triton X-100, 0.5% deoxycholate). The lysates were cleared via 5 min of centrifu-
gation at 500 g, supplemented with 0.5 mM Pefabloc, and precipitated with 5 volumes of methanol at 
− 20 °C. Samples were then centrifuged at 10000 × g for 30 min, and the pellets were re-dissolved in TNE 
buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM EDTA). Enzymatic digestions with PNGaseF (New 
England Biolabs) were performed for 1 h at 37 °C80. After digestion, the reactions were stopped by the 
addition of Laemmli buffer and PrP analyzed via immunoblotting using the POM17 antibody.
Western blot analysis. The samples were resolved using SDS-PAGE (13.5% acrylamide gels) and 
electrophoretically transferred onto PVDF. The membranes were blocked for 1 h in 5% (w/v) non-fat 
dried skimmed milk powder in Tris-buffered saline containing 0.05% Tween 20. After incubation 
with mouse anti-PrP POM17 and HRP (horseradish peroxidase)-conjugated goat-anti mouse antibody 
(Sigma-Aldrich, 1:5000), the signals were developed using an ECL-Western-blotting reagent (Bio-Rad) 
and detected using ChemiDoc XRS equipment.
Statistical analysis of experiments. Statistical analysis of experiments was performed either using 
paired Student’s t-test, for comparing two samples, or one-way ANOVA with Dunnett’s post-hoc test, for 
comparison of all columns to a control column. Results are displayed as the average of replicates ± s.d.
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